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Abstract: Inflammatory bowel disease (IBD) is characterized by chronic remitting and relapsing
inflammation of the lower gastrointestinal tract. The etiology underlying IBD remains unknown,
but it is thought to involve a hypersensitive immune response to environmental antigens, including
the microbiota. Diagnosis and monitoring of IBD is heavily reliant on endoscopy, which is
invasive and does not provide information regarding specific mediators. This review describes
recent developments in imaging of IBD with a focus on positron emission tomography (PET) and
single-photon emission computed tomography (SPECT) of inflammatory mediators, and how these
developments may be applied to the microbiota.
Keywords: Inflammatory Bowel Disease (IBD), colitis; PET; SPECT; microbiota; cytokine; chemokine;
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1. Introduction
Inflammatory bowel disease (IBD) is an inflammatory disorder of the gastrointestinal (GI) tract
that impacts substantially on quality of life. The causes of inflammation in IBD remain unknown, but
are thought to involve a hypersensitive immune response to the intestinal microbiota. IBD is commonly
associated with dysbiosis, but it remains unknown whether dysbiosis is a cause or consequence of
inflammation. Diagnosing and monitoring IBD is heavily reliant on endoscopy, which is an invasive
technique that requires bowel preparation and typically also anesthesia. Although generally well
tolerated, endoscopy noticeably impacts on patient quality of life and does not provide any direct
information regarding the role that specific mediators contribute toward inflammation. Therefore,
new technologies are required that are sensitive enough to grade disease severity, are non- or only
minimally invasive, and can be optimized for the detection of specific mediators. Recent developments
in positron emission tomography (PET), particularly with the use of antibody-conjugated tracers, have
demonstrated success in cancers, but have only recently been adapted to IBD. This review summarizes
the current advances of these technologies in IBD, how they have been used to detect specific mediators
of inflammation, and their potential to image microbiota.
2. Inflammatory Bowel Disease
IBD is a collection of debilitating idiopathic diseases characterized by chronic inflammation of the
lower gastrointestinal tract that have a remitting and relapsing disease course. The cause(s) of IBD
remain unknown; however, they are thought to involve aberrant immune responses to environmental
stimuli in people with a complex genetic predisposition. The global prevalence of IBD is estimated
to be 0.3% and is widely regarded as increasing [1]. The relatively recent increase in the incidence of
IBD is perplexing and highlights the likely importance of yet-to-be-determined environmental factors
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in its etiology. IBD is typically diagnosed in adolescence and early adulthood; however, it can also
occur in the very young pediatric population, and approximately 25% of pediatric cases present prior
to reaching 10 years of age [2,3]. It is currently unclear whether the mechanisms underlying IBD
differ between the very young pediatric and late adolescent populations. However, it is probable that
yet-to-be-characterized genetic factors feature more prominently in the very young, as the length of
time of exposure to environmental factors is unlikely to be long enough to sensitize the developing
immune system. IBD is a chronic disease in pediatric and adult populations; however, the pediatric
population is particularly vulnerable to the consequences of IBD, including impacts on growth and
development, bone health, and psychosocial function and development [2].
There are two major subtypes of IBD: Crohn’s disease (CD) and ulcerative colitis (UC), which
can typically be distinguished by pathological and histological differences. Inflammation in UC is
typically restricted to the mucosal layer of the colon and progresses in a contiguous manner. CD differs
in that it is characterized by transmural skip lesions that can occur anywhere in the GI tract but are
typically located in the ileum with and without involvement of the colon. The initiating factors and
inflammatory aspects are likely to differ between CD and UC given the distinctions between their
pathology, but are only poorly understood relative to what is known regarding how inflammation is
perpetuated. This increased understanding has led to the relatively recent development of biologic
drugs targeting specific immune mechanisms, most prominently the cytokines TNF-α, interleukin
(IL)-12 and -23, and integrins involved in the migration of immune cells into the GI tract, including
α4β7 [4]. These treatments and other nonspecific immune suppressants can be beneficial in IBD;
however, treatment gaps remain due to intolerance, incomplete efficacy, and side effects of current
therapies, leading to a disease course characterized by variable periods of remission and relapse.
Prognostic indicators of relapse in IBD are only poor, and therefore patients are required to undertake
constant surveillance, typically via endoscopy. Severe persistent or relapsing symptoms also lead to
fibrosis and stricture in >30% of CD and approximately 5% of UC patients [5]. Intestinal fibrosis and
stricture occurs as a result of excessive deposition of extracellular matrix proteins that accumulate
following tissue remodeling and lead to serious complications, including obstructions [6]. No drugs
are currently clinically available to treat fibrosis and stricture, and therefore these cases often lead to
surgery, which can be curative for UC (withstanding complications), but is not curative for CD [7].
This high rate of surgery highlights the ongoing need for a deeper understanding of the mechanisms
involved in initiating and perpetuating inflammation in IBD.
Imaging IBD: Current Approaches
Treatments for IBD depend on clinical severity, which is typically assessed by endoscopy.
The gastrointestinal mucosa is directly imaged by endoscopy for assessment of disease stage and
monitoring, and when forceps are attached, which allows for the collection of biopsy material for
analysis of pathology and mechanistic studies. Endoscopy can differentiate between UC and CD in the
majority of cases [8]. However, endoscopic approaches have limitations, as the quality of results is
operator-dependent and it may not be sensitive enough for assessment of clinical severity in some
cases. Furthermore, endoscopic imaging is restricted to the superficial mucosal layers of the intestine
and therefore provides no information regarding inflammatory damage to the deeper layers of the
intestinal wall, the degree of muscle thickness, or the diameter of the lumen. Finally, a major limitation
of endoscopy is the difficulty in reaching the small intestine, due to the distance needed to be covered
and the complexities of intestinal anatomy with its multiple loops and folds. These limitations are
particularly relevant to the pediatric population, who are sensitive to perforation of the intestinal wall
and risks associated with sedation [9].
A number of novel imaging technologies are emerging that complement or may even replace
endoscopy as the gold standard for clinical diagnosis, as recently reviewed in detail [10,11].
Chromoendography involves the application of dyes onto the mucosa, improving endoscopic
characterization of lesions and neoplasia, and has the potential to correlate with histological damage,
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although the latter remains controversial [12]. Confocal laser endomicroscopy and endocytoscopy
combine high-resolution microscopic imaging with endoscopy, and again, are primarily used to detect
colonic dysplasia and neoplasia [13]. Wireless capsule technologies may circumvent the limitations that
endoscopy has in accessing difficult-to-reach areas of the small intestine. While these capsules provide
high-resolution imaging, they have similar limitations to standard endoscopy regarding assessment of
inflammatory damage to the deeper layers of the colon wall and may also require surgery for removal
when stricture occurs [14,15].
Less invasive imaging technologies include barium X-rays, ultrasound, magnetic resonance
imaging (MRI), computed tomography (CT), PET, and single photon emission computed tomography
(SPECT). Barium X-rays provide excellent visualization of the bowel and can reveal thickening of
the bowel wall, but are not recommended in patients with severe inflammation due to the risk
of complications such as toxic megacolon, and while they have been traditionally used to assess
stricture location and severity, this is largely being replaced by CT and MRI [2]. Ultrasound, MRI,
CT, PET, and SPECT are minimally invasive relative to endoscopy and offer the additional benefits
of visualizing planes through the colon wall and extraintestinal manifestations. Bowel ultrasound
has some attractions as a noninvasive diagnostic tool for IBD, including relative inexpensiveness,
high accuracy in CD, and ease of use. It has recently been used to reveal ulcer location and severity
in adult CD, and ultrasound and MRI are currently the preferred tools for assessment of pediatric
perianal abscesses and fistulas [16–18]. However, ultrasound is highly operator-dependent and its
accuracy is sensitive to anatomical location, as it is reduced for detecting ulcers in the jejunum and
rectum [17,18]. MRI is currently the imaging technique of choice for follow-up of CD patients due
to its lack of ionizing radiation. Notably, MRI can differentiate between normal and pathological
sections of the bowel by analysis of changes in bowel wall thickness [19]. Recent developments with
MRI and CT include using them to assess fibrosis and stricture. Gadolinium-contrasted MRI has
recently been shown to reliably predict severe fibrosis in CD and, interestingly, also revealed that
areas of fibrosis often coexist with inflammation within the same intestinal segment [20]. A recent
comprehensive review of the use of PET/SPECT for IBD diagnosis, prognosis, and follow-up indicated
that 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) coupled with CT has the highest accuracy for detecting
inflammation in IBD [11]. 18F-FDG is a radiolabeled glucose analogue that detects tissue glucose
metabolism and has been the tracer of choice for PET studies for decades; however, radiolabeled
leukocytes are also typically used to assess GI inflammation. Indeed, SPECT of technetium-99m
(99mTc)-leukocytes was shown nearly two decades ago to accurately assess the extent and severity of
disease for people with severe UC, correlating with endoscopic and histological findings [21]. However,
limitations with radiolabeled leukocytes exist, including a relatively extensive protocol required for
working up the cells, risks of cross-contamination, and importantly, the nonspecific nature of the
tracer. Only limited information exists regarding the use of PET, SPECT, or CT for pediatric IBD,
although the combination of 18F-FDG PET/CT has been suggested to be the most reliable due to its
improved anatomical mapping [22]. Importantly, 18F-FDG dosing and imaging protocols are yet to
be standardized for PET of pediatric patients, highlighting the need for more studies in this area.
Nonetheless, the potential benefits of PET/CT in the pediatric IBD population were highlighted in
the first published case, where scans in a 12-year-old child revealed diffuse heterologous uptake of
18F-FDG in the gut wall, particularly in the stomach [23]. CT confirmed that the uptake was focal, and
endoscopy revealed ulceration of the gastric wall, with an ensuing diagnosis of gastric and intestinal
CD. It is important to note that while these technological advances are welcome for IBD management,
none of them currently target specific mediators. This highlights the need for the development of new
imaging technologies that are highly sensitive, quantitative, and able to provide longitudinal data in
real time, but are also only minimally invasive.
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3. Imaging Inflammatory Mechanisms in IBD: Which Targets to Choose?
3.1. Immune Targets
Inflammation is central to IBD; however, much remains to be understood regarding the causes
of inflammation in humans. It is currently thought that inflammation in IBD is driven by a loss
of immune tolerance to autologous proteins in the colon wall and foreign antigens in the lumen,
including the microbiota. This initiates a cascade of cytokines and chemokines which cause an influx
of immune cells, as comprehensively reviewed elsewhere [24,25]. Immune cells are attracted to sites of
inflammation by chemokines and also by upregulated expression of “gut-homing” integrins on the
cell surface, including α4β7 [26]. Subsequent inflammatory lesions and damage to the epithelial wall
and deeper layers of intestinal tissue result in the production of damage-related mediators during
active disease, which progresses toward mediators related to tissue-remodeling and wound healing as
disease improves toward remission, but also toward mediators associated with fibrosis after repeated
or extended periods of inflammation. The immunological basis for the differences in pathophysiology
of UC and CD are not clear, and while it is suggested that CD is driven by a TH1/TH17-type immune
response and UC is mediated by a TH2-type immune response (↑ IL-5, IL-13) that is atypical as IL-4 is
not involved, much of the evidence for this generalization results from animal models. Furthermore,
while there is evidence supporting a genetic predisposition, large-cohort IBD human studies indicate
this is clearly complicated and contains loci that coexist in both CD and UC, but also other loci that
are not shared [27,28]. Environmental factors are thought to contribute to IBD; however, evidence for
or against these are heavily biased toward animal studies and are yet to be definitively determined
in humans. The best evidence supporting an aggravating role for specific immune mediators in IBD
is the success of several biologic medications targeting the cytokines TNF-α and IL-12/23 and the
gut-homing integrin α4β7. This success is tempered by the lack of efficacy of therapies directed against
IL-17, IFN-γ, and IL-13, amongst others [29]. However, as failure of biologics in the clinic can be related
more to toxicity and side effects than to a lack of involvement of their target, tracers directed to these
cytokines may still prove to be valuable for imaging. With this in mind, new immune modulators are
currently undergoing clinical trials, including those targeting specific cytokines such as IL-6, inhibitors
of intracellular pathways including Janus kinases (JAK), and mediators related to tissue remodeling
and fibrosis, such as matrix metalloproteases (MMP) [29].
Recent advances in two-photon laser scanning microscopy have enabled in vivo imaging of
deep visceral tissues and immune cells in particular, indicative of the potential for this technique
to provide preclinical evidence prior to relatively expensive immuno-PET studies. Two-photon
laser scanning microscopy was instrumental in identifying goblet cell-associated passage (GAPs)
as the major mechanism for delivering luminal antigens to dendritic cells in the small intestine in
health [30]. Interestingly, GAPs only appear in the colon following the disruption of microbe-sensing
pathways, highlighting a potential role in IBD [31]. We have recently applied two-photon laser
scanning microscopy to investigate immune cell migration in the trinitro benzene sulphonic acid
(TNBS) model of colitis, demonstrating in vivo that not only are immune cells in very close apposition
to nerves within the colon wall, but also that myeloid cell infiltration is increased in TNBS colitis [32].
This technique can be easily combined with reporter mice and promises to increase the understanding
of the mechanisms involved in immune cell migration from blood vessels into the lower GI tract
in IBD.
3.2. Microbiota
Recent improvements in high-throughput “omics” technology have also revealed the involvement
of the microbiome in IBD. The general consensus indicates that active IBD is characterized by an overall
loss of diversity coupled with a dysbiotic phenotype primarily depicted by elevated Proteobacteria
and decreased Firmicutes, although inconsistencies between studies remain [33–35]. Functionally, the
major classes of bacteria affected relate to the production of short-chain fatty acids (e.g., Faecalibacerium
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prausnitzii), bacteria with mucolytic activity (e.g., Ruminococcous torques), and sulfate-reducing species
including Desulfovibrio [36–38]. While this dysbiotic composition may contribute to disease progression
through dysregulated epithelial barrier function and aberrant immune signaling, it is currently
contentious whether dysbiosis itself causes IBD or simply reflects the disease course [39].
Uncovering the compositional shifts in the microbiome has undoubtedly increased our
understanding of its role in disease initiation, progression, and relapse. However, techniques such as
16S pyrosequencing are inherently limited by the variations that exist in aspects of their methodology,
including inconsistent or incomplete reference libraries, the unknown impact of batched analyses,
nonstandardized statistical analyses, and an inability to adequately appreciate the heterogeneity in
the microbiome [40]. This is further confounded by the fact that the annotation is based on putative
association of the 16S rRNA gene, with a taxon defined as an operational taxonomic unit (OTU) [41,42].
Although whole-genome shotgun sequencing has enhanced our ability to define species taxa with more
accuracy, it remains an expensive alternative to 16S and requires significantly greater data analysis [40].
As such, conclusions regarding the functional implications of compositional shifts remain difficult
to draw, relying on metagenomic inference using phylogenetic investigation of communities by
reconstruction of unobserved states (PICRUSt). Nonetheless, changes in microbiota composition offer
the intriguing potential to image microbiota as markers of disease severity in IBD.
4. PET and SPECT of Specific Mediators in IBD
PET of radioisotope-labelled antibodies is currently being used in multiple clinical trials in cancer
to tailor personalized therapies based on specifically targeted diagnostic tests [43,44]. However,
immune-PET of IBD is currently limited to preclinical studies. When deciding which inflammatory
mediators to image in IBD, it is firstly important to understand which immune processes are likely to
be involved in the model of choice, and secondly to understand what the information will provide
regarding the initiating, perpetuating, and resolving phases of colitis.
4.1. Imaging Colitis in Animal Models
Animal models of colitis have significantly improved our understanding of how inflammation
develops and perpetuates, highlighting roles for both the innate and adaptive arms of the immune
response. There are currently numerous animal models of IBD, including colitis that develops due to
primary genetic defects, adoptive transfer of activated immune cells, or is chemically induced [45].
Importantly, most of these models progress directly from acute through to fulminant colitis and
therefore are not useful for investigating pathways involved in the resolution of inflammation and
tissue remodeling. Nuclear imaging of colitis has so far relied upon two models of chemically induced
colitis: the TNBS model and the dextran sulfate sodium (DSS) model. TNBS is administered by enema
and inflammation is therefore restricted to the colon. TNBS is a hapten; it is not directly toxic, but
instead binds to autologous proteins and luminal microbiota, turning them immunogenic. The colitis
that develops is transmural, involves an IL-12-driven TH1/TH17-type response, and is therefore
considered to model aspects of inflammation associated with CD [46]. DSS differs as it is directly
toxic to epithelial cells and, when administered by the oral route in drinking water, results in a colitis
that takes longer to develop than TNBS. DSS colitis is considered to model aspects of inflammation
associated with UC as the colitis results from direct damage to the epithelial layer and is not as deep
as that which occurs with the TNBS model. While animal models are useful for emphasizing the
importance of specific mediators and mechanisms, it is important to note that findings from animal
models can be difficult to translate to human IBD. This is common with most chronic diseases that
have a remitting and relapsing course due to the involvement of multiple and overlapping pathways
that are intertwined with disease stage as inflammation progresses and regresses, highlighting the
requirement for extensive validation in human subjects.
Int. J. Mol. Sci. 2018, 19, 2471 6 of 13
4.1.1. PET and SPECT of Immune Mediators in Colitis
Cell-secreted immune mediators are generally classified as chemokines or cytokines,
with chemokines mediating cell attraction and cytokines mediating immune responses. Table 1
provides an overview of PET/SPECT studies of immune mediators in human IBD and animal models
of colitis. The first study investigating whether radiolabeled antibodies are efficacious for imaging
colitis was disappointing, as uptake of 111In-labelled IgG was substantially lower than 111In-labelled
leukocytes, the gold standard at the time, and also the newly developed 111In-labelled liposomes in
TNBS-colitic rabbits [47]. While imaging of liposomes and leukocytes enabled grading of inflammation,
the contrast provided from IgG labelling was not sufficient for this to occur. This result was not
surprising given the large abundance of IgG in circulating blood and its relative nonselectivity for
colitis. Interleukin (IL)-8, more recently renamed CXCL8, is a chemokine produced by innate immune
cells, but also cells in other tissues, including epithelial cells and endothelial cells. IL-8 is primarily
involved in attracting neutrophils to inflammatory sites, but also attracts other granulocytes, including
mast cells. Colonic inflammation in TNBS-treated rabbits was detected more readily with 99mTc-labelled
IL-8 than 99mTc-labelled granulocytes [48]. Furthermore, the severity of inflammation was also able
to be graded with 99mTc-IL-8, but not with 99mTc-granulocytes. More recently, IL-8 was labelled
with 99mTc for SPECT studies and was found to have higher sensitivity for detecting inflammation
than endoscopy in a large clinical study of people with IBD, although specificity was lower than for
endoscopy [49]. TNF-α is a cytokine that is secreted by a range of immune cells from both the innate
and adaptive arms of the immune response and is produced in large amounts in many autoimmune
diseases, including IBD. Neutralizing TNF-α with antibodies, for example infliximab, has proven
success in treating IBD [50,51]. In preclinical studies, 99mTc-labelled infliximab was able to discriminate
between moderate and severe colonic inflammation in TNBS-treated rats [52]. However, enthusiasm
for infliximab as a tracer in preclinical studies was hampered by high background uptake in healthy
control rats. This study is of importance as it not only revealed TNF-α mediated inflammation, but
it also demonstrated target specificity of a clinically useful drug for IBD. This is also particularly
significant given the increased development of biologics, particularly antibody-based therapies, but
also the relatively recent expansion of personalized medicine and theragnostic approaches toward
treating disease.
Table 1. Summary of PET/SPECT of human IBD and animal models of colitis. - Not suitable for colitis
imaging, + satisfactory image quality, ++ excellent image quality.
Target Tracers Species Model Outcome Reference
Leukocytes 99mTc-HMPAO-leukocytes Humans UC + [21]
CXCL8 99mTc-CXCL8 Humans CD and UC + [49]
β7








CD4 89Zr-GK1.5 cys-diabody Mice DSS ++ [55]











Abbreviations: UC: ulcerative colitis. CD: Crohn’s disease. DSS: dextran sulphate sodium. TNBS: tri-nitro benzene
sulphonic acid. WBC: white blood cell. Tc: technetium.
4.1.2. Imaging Immune Cells in Colitis
The DSS colitis model is the most commonly used model to image immune cells in colitis. Table 1
provides an overview of PET/SPECT studies of immune cells in human IBD and animal models of
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colitis. The integrins α4 and β7 form a heterodimer (α4β7) which specifically directs the migration,
or homing, of immune cells to the gastrointestinal tract via interactions with its ligand, the addressin
MAdDCAM-1 [26]. Targeting this pathway has proved successful in IBD with the recent development
of vedolizumab, a monoclonal antibody that blocks α4β7 [56]. Uptake of 64Cu-labelled β7 antibodies
is increased in DSS-colitic mice relative to healthy controls and also to 64Cu-labelled IgG isotype
negative control, indicating the potential for β7 as a tracer for human IBD [53]. However, high levels
of background were also observed in nontarget organs including the small intestine and stomach,
prompting the development of antibody fragments. In the same model, uptake of 64Cu-labelled β7
antibody fragments was superior to both whole 64Cu-labelled β7 antibodies and 64Cu-labelled α4β7,
suggesting that antibody fragments may provide enhanced signaling of inflammation in IBD compared
to whole antibodies [54]. The concept of increased sensitivity with small antibodies has recently been
validated in cancer biology and in inflammation. 18F-labelled antibody fragments directed against the
antigen-presenting complex major histocompatibility complex (MHC)II were much more sensitive
than standard 18F-FDG in detecting xenoplanted tumors, even detecting tumors when growth was
neither palpable nor visible [57]. Furthermore, 18F-labelled antibody fragments directed against CD11b
detected complete Freund’s adjuvant (CFA)-induced inflammation in the mouse paw much earlier
than standard 18F-FDG [57]. Most recently, 89Zr-labelled antibody fragments against the THELPER
marker CD4 were observed to have higher uptake in the colon of DSS mice compared to healthy
controls [55]. However, uptake was also increased in the spleen and lymph nodes, highlighting the
intrinsic difficulties in imaging immune cells during inflammation, as they generally migrate to and
from inflammatory sites and lymph nodes, incorporating blood vessels and lymphatics.
4.2. Imaging the Microbiota in Colitis
As our understanding of microbiota–host interactions grows, it is necessary to move beyond
current genomics technology and compositional descriptions. This remains a daunting task when
imaging specific microbiota in the gut, as it is limited by the diversity of tissue types that need to be
maintained, which is of particular importance when considering the sensitivity of the mucous layer
to standard fixation methods and the heterogeneity within gut microenvironments. As such, it is
critical that a robust protocol including mucous-preserving sample preparation, image segmentation,
and quantitative analysis tools be developed. A framework satisfying these criteria was recently
developed by Earle et al. [58], where high-resolution quantification of the spatial organization of the
gut microbiome revealed that changes in the proximity of microbes to the epithelium are sufficient
to induce increased expression of key inflammatory markers, despite negligible shifts in microbiota
composition. Most recently, chemical imaging techniques exploiting a blinking surface enhanced
Raman spectroscopy (SERS) have been used to visualize bacteria in vitro with exquisite resolution,
and have demonstrated the ability to differentiate between the chemical signatures of different
bacteria [59]. MRI, CT, fluorescence/bioluminescence imaging, and PET have also been applied to
investigate the activity of bacteria in vivo; however, these typically only provide indirect information
about bacterial activity by inference from immune function [60,61]. Recent advances exploiting
the bacterial uptake of carbohydrates have proven successful for the selective in vivo imaging of
bacteria independently of host factors and secondary pathologies [61,62]. Furthermore, specific
bacteria have also been labelled with iron oxide nanoparticles for MRI to track bacteria longitudinally
during infection [60]. These developments highlight the potential to image specific bacteria during
inflammation, but are yet to be applied to IBD.
5. Limitations of Radiolabeled Antibodies
Despite the evidence outlined above supporting the potential use of radiolabeled antibodies or
immune mediators for in vivo diagnostic imaging, several issues remain that currently limit enthusiasm
for widespread use. The primary limitation is economy-based, as specialized equipment is required for
the manufacture and detection of radiolabels. These costs are high, but may be mitigated by improved
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clinical outcomes, including early detection, and the potential development of personalized medicines
to improve clinical responses and reduce side effects. Scientific challenges also exist, particularly with
relation to the relatively long half-life of antibodies and the time required for them to move through
the circulatory system to the site of inflammation and clear after studies have been performed. These
issues relate to the increased risk of cancer due to radiation exposure, particularly as IBD patients
already have a higher risk of colon cancer. However, PET is considered safe and the effective dose
of whole-body 18F-FDG was approximately 7 mSv, much less that the 16 mSv used for a routine
abdominal–pelvic CT with contrast [63,64]. Notable efforts are underway to reduce circulation time
by using pretargeted methods, as explained in more detail below. The relatively large structure of
antibodies may lead to difficulties in penetration of the site of inflammation, although this may be
mitigated by altering the structure of the antibody, also explained in more detail below. A limitation
also relates to the single mode of PET detection, as only a single mediator can be imaged. This is
problematic in terms of detailed studies of immune cell subsets, as they are typically identified by
flow cytometry techniques requiring multiple targets. Furthermore, mediators must be accessible to
antibodies and are therefore restricted to soluble cytokines and chemokines or markers located on the
outer surface of the cell membrane. While intracellular cytoplasmic cytokines and nuclear transcription
factors such as FOXP3 (TREG) and ROR-γ (TH17) are increasingly being used to characterize immune
cell subsets, antibody penetration inside immune cells typically requires cell permeabilization, which
is not possible in vivo.
6. Future Directions for Imaging IBD
Remarkable progress has been achieved in recent years toward understanding the mechanisms
underlying IBD. This has resulted in a number of specific biologics for treatment, but they are yet
to be applied to diagnosis or surveillance. The complex immunological mechanisms of IBD indicate
that there are multiple markers that could potentially be used for diagnostic imaging and drug
bioavailability. Imaging specific sites of inflammation should be achievable relatively easily; however,
determining markers that differentiate between IBD and other gastrointestinal diseases, such as cancer,
is more problematic and requires extensive preclinical validation.
Intact antibodies are increasingly being used as therapeutics; however, their utility as imaging
agents is reduced by their extended half-life, as the duration of time required to reach a sufficient
signal-to-noise ratio is long. Furthermore, extended half-lives may also lead to other harmful biological
activity and side effects, potentially altering the biological function being imaged; however, in theory,
this risk is minor as concentrations are much typically much lower for imaging than for treatment.
Recent developments in antibody engineering include a shift from whole IgG antibodies to fragments,
enhancing their physical properties and leading to enhanced efficacy as extensively reviewed in [65].
Enzymatic cleavage or restructuring of the antibody attenuates problems associated with half-life by
decreasing clearance times. Furthermore, decreasing the amount of time required to reach a suitable
signal also permits the use of short-lived isotopes, reducing radiation exposure.
Pretargeting strategies have also emerged as a means of improving efficacy whilst reducing
radiation dose; for example, by using a novel biorthogonal inverse electron demand Diels–Alder
reaction between a 64Cu-labelled radioligand and a site-specific immunoconjugate [66]. This occurs in
four steps: (a) injection of the modified antibody, (b) accumulation of the antibody at its target site and
clearance from the blood, (c) injection of the radioligand 24 h later, and (d) the in vivo click ligation
between the immunoconjugate and radioligand and subsequent excretion of excess radioligand.
The target was able to be delineated four hours post-injection of the radioligand in tumor tissue,
with image contrast improved over time and an ideal signal-to-noise ratio at 24 h. This pretargeting
approach and similar approaches may expedite the clinical translation of future immunoconjugates
for imaging.
A tantalizing approach is the potential to image different bacterial species; however, this is again
currently limited by the lack of knowledge of functional roles for specific microbiota in IBD and the
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limited ability of PET to simultaneously label multiple targets. Furthermore, imaging of microbiota in
general currently requires models where the bacteria can be isolated, labelled, and readministered.
Future developments including the ability to use multiple labels, but also advances in the identification
of bacterial species of interest and anaerobic culturing of microbiota, would be a welcome addition
to preclinical models of IBD in the first instance before clinical studies are warranted. Furthermore,
the potential to exploit factors that are selectively produced by bacteria and differentiate between
active and quiescent states may provide intriguing insights. Bacterial toxins may be the ideal sensor as
they are typically only secreted during disease, are readily identifiable by antibodies, and are relatively
easily attached to various detection technologies. However, biosensing technology remains limited in
its ability to provide insight into the spatial organization of the microbiome, and as such, the ideal
microbial analysis tool remains elusive and current investigations must combine genomic, visual,
and activity-based measures.
7. Summary
Imaging has a critical role in the diagnosis and management of IBD patients, where endoscopic
studies are currently the gold standard. However, there is a clear need for new technologies that are
less invasive than endoscopy, but more penetrative at both the local level within the intestinal wall and
more broadly along the entire intestinal length. These factors are most relevant for pediatric IBD, where
risks of adverse outcomes are increased, and also in small intestinal inflammation and fibrosis, which
is generally not accessible by endoscopy. Animal studies indicate that PET and SPECT of immune cells
and/or mediators are potentially useful for IBD management and diagnosis. The potential targets
for PET/SPECT of immune mediators and cells in active IBD are numerous; however, options for
imaging of microbiota are currently limited by the lack of understanding of the role that specific
microbiota contribute toward IBD. Translation of these technologies into human studies in IBD is
currently nonexistent, yet applicability in other diseases such as cancer is encouraging. Imaging of
currently available biologics should be relatively achievable in the short term, while longer-term goals
include the development of tracers with deep tissue penetration and short half-lives. Concurrent
research into the immune mechanisms underlying IBD should deliver targets that offer insight into
disease mechanisms, for example in pediatric IBD, and can differentiate between diseases and/or
disease states, for example between active inflammation and fibrosis in UC and CD. In conclusion, the
future for the development of imaging techniques in IBD is bright, and further refinement will clearly
lead to benefits in the diagnosis and management of IBD patients.
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CD4 Cluster of differentiation 4
CD11b Cluster of differentiation 11b
CFA Complete Freund’s adjuvant
CT Computed tomography
CXCL8 C-X-C motif chemokine ligand 8; interleukin 8
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MAdCAM-1 Mucosal vascular addressin cell adhesion molecule 1
MHCII Major histocompatibility complex II
MMP Matrix metalloproteinase
MRI Magnetic resonance imaging
mSv Milliseiverts
OTU Operational taxonomic unit
PET Positron emission tomography
rRNA Ribosomal ribonucleic acid
SERS Surface enhanced Raman spectroscopy
SPECT Single photon emission computed tomography
TNBS Trinitro benzene sulfonic acid
TNF-α Tumor necrosis factor alpha
UC Ulcerative colitis
VHH Variable domain of heavy-chain antibodies
WBC White blood cell
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